Tullio Sulser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7688255/publications.pdf

Version: 2024-02-01

71 1,571 21 36 g-index

73 73 73 73 2778

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Prostate cancer detection rate in men undergoing transperineal templateâ€guided saturation and targeted prostate biopsy. Prostate, 2022, 82, 388-396.	1.2	15
2	Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria. World Journal of Urology, 2021, 39, 97-103.	1.2	13
3	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. Prostate, 2021, 81, 286-294.	1.2	4
4	Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5–15 mm: Results of a Randomized Controlled Trial. European Urology Open Science, 2021, 25, 5-10.	0.2	7
5	Impact of shortâ€ŧerm Dutasteride treatment on prostateâ€specific membrane antigen expression in a mouse xenograft model. Cancer Reports, 2021, 4, e1418.	0.6	2
6	Tumor stent for chronic ureteral obstruction: Which are predictors of stent failure?. Journal of Endourology, $2021, \ldots$	1.1	3
7	Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorship. World Journal of Urology, 2020, 38, 741-746.	1.2	4
8	Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau). World Journal of Urology, 2020, 38, 2485-2491.	1.2	5
9	Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2829-2841.	1.2	23
10	Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 822-829.	2.2	10
11	Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 683.e19-683.e26.	0.8	12
12	Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist, 2020, 25, 585-590.	1.9	22
13	External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. Journal of Urology, 2020, 203, 719-726.	0.2	23
14	Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. Journal of Urology, 2020, 203, 949-956.	0.2	30
15	Reply by Authors. Journal of Urology, 2020, 203, 956-956.	0.2	O
16	Is loss of power output due to laser fiber degradation still an issue during prostate vaporization using the 180ÂW GreenLight XPS laser?. World Journal of Urology, 2019, 37, 181-187.	1.2	3
17	Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer. World Journal of Urology, 2019, 37, 351-358.	1.2	18
18	CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors. BMC Cancer, 2019, 19, 802.	1.1	4

#	Article	IF	Citations
19	A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3037-3045.	1.2	16
20	Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. Journal of Cancer Research and Clinical Oncology, 2019, 145, 781-785.	1.2	14
21	Concentrationâ€dependent effects of dutasteride on prostateâ€specific membrane antigen (PSMA) expression and uptake of 177 Luâ€PSMAâ€617 in LNCaP cells. Prostate, 2019, 79, 1477-1483.	1.2	5
22	Pure Bipolar Plasma Vaporization of the Prostate: Results from a Prospective 3D Ultrasound Volumetry Study with Clinical Outcome After 3 Years. Journal of Endourology, 2019, 33, 107-112.	1.1	0
23	Combined Nâ€terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Prostate, 2019, 79, 206-214.	1.2	18
24	Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer. World Journal of Urology, 2019, 37, 1837-1844.	1.2	16
25	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 889-900.	3.3	44
26	Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. Journal of Urology, 2019, 202, 717-724.	0.2	46
27	Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy. British Journal of Cancer, 2018, 118, 825-830.	2.9	58
28	Pharmacological upregulation of prostateâ€specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate, 2018, 78, 758-765.	1.2	48
29	Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi. CKJ: Clinical Kidney Journal, 2018, 11, 364-369.	1.4	23
30	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. Journal of Urology, 2018, 200, 309-318.	0.2	43
31	Prevalence and causes of abnormal PSA recovery. Clinical Chemistry and Laboratory Medicine, 2018, 56, 341-349.	1.4	3
32	Prevalence of hypertension and diabetes after exposure to extracorporeal shock-wave lithotripsy in patients with renal calculi: a retrospective non-randomized data analysis. International Urology and Nephrology, 2018, 50, 1227-1233.	0.6	4
33	Injected Human Muscle Precursor Cells Overexpressing PGC-1 <i>α</i> Enhance Functional Muscle Regeneration after Trauma. Stem Cells International, 2018, 2018, 1-11.	1.2	6
34	Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction. Neurourology and Urodynamics, 2018, 37, 2414-2424.	0.8	5
35	Expression of Indoleamine 2,3-Dioxygenase Induced by IFN- \hat{I} 3 and TNF- \hat{I} 4 as Potential Biomarker of Prostate Cancer Progression. Frontiers in Immunology, 2018, 9, 1051.	2.2	63
36	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	0.8	44

#	Article	IF	Citations
37	The role of donor age and gender in the success of human muscle precursor cell transplantation. Journal of Tissue Engineering and Regenerative Medicine, 2017, 11, 447-458.	1.3	8
38	Polyesterurethane and acellular matrix based hybrid biomaterial for bladder engineering. , 2017, 105, 658-667.		21
39	Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. Prostate, 2017, 77, 549-556.	1.2	34
40	Detecting circulating tumor DNA in renal cancer: An open challenge. Experimental and Molecular Pathology, 2017, 102, 255-261.	0.9	28
41	Extraction Strings for Ureteric Stents: Is There an Increased Risk for Urinary Tract Infections?. Surgical Infections, 2017, 18, 936-940.	0.7	17
42	Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry. World Journal of Urology, 2017, 35, 429-435.	1.2	4
43	Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. Oncotarget, 2017, 8, 21871-21883.	0.8	12
44	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. Oncotarget, 2017, 8, 31765-31774.	0.8	15
45	Magnetic stimulation supports muscle and nerve regeneration after trauma in mice. Muscle and Nerve, 2016, 53, 598-607.	1.0	26
46	A positive family history as a risk factor for prostate cancer in a populationâ€based study with organised prostateâ€specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (<scp>ERSPC</scp> , Aarau). BJU International, 2016, 117, 576-583.	1.3	36
47	Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (<scp>ERSPC</scp>) and Prostate Cancer Prevention Trial (<scp>PCPT</scp>) risk calculators: independent validation and comparison in a contemporary European cohort. BJU International, 2016, 117, 401-408.	1.3	76
48	Stem Cells in Functional Bladder Engineering. Transfusion Medicine and Hemotherapy, 2016, 43, 328-335.	0.7	16
49	Clinical impact of prostate biopsy undergrading in an academic and community setting. World Journal of Urology, 2016, 34, 1481-1490.	1.2	6
50	External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC. Journal of Urology, 2016, 196, 1402-1407.	0.2	8
51	Hybrid Randomly Electrospun Poly(lactic- <i>co</i> glycolic acid):Poly(ethylene oxide) (PLGA:PEO) Fibrous Scaffolds Enhancing Myoblast Differentiation and Alignment. ACS Applied Materials & Samp; Interfaces, 2016, 8, 31574-31586.	4.0	35
52	Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering. Journal of Nuclear Medicine, 2016, 57, 1467-1473.	2.8	12
53	Absorption of irrigation fluid during XPSâ,,¢ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study. World Journal of Urology, 2016, 34, 1261-1267.	1.2	10
54	Predictive value of low tube voltage and dual-energy CT for successful shock wave lithotripsy: an in vitro study. Urolithiasis, 2016, 44, 271-276.	1.2	10

#	Article	IF	CITATIONS
55	Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years. Clinical Genitourinary Cancer, 2016, 14, 290-297.	0.9	8
56	L1-CAM is commonly expressed in testicular germ cell tumours. Journal of Clinical Pathology, 2016, 69, 460-462.	1.0	3
57	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. Journal of Pathology Informatics, 2016, 7, 3.	0.8	10
58	Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncology Letters, 2015, 10, 2753-2760.	0.8	13
59	CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. Disease Markers, 2015, 2015, 1-8.	0.6	34
60	Acute Abdominal Pain Accompanied by High Creatinine in a Female Patient With Schizophrenia. Urology, 2015, 85, 495-498.	0.5	4
61	pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 889-898.	3.2	55
62	Differentiated adipose-derived stem cells for bladder bioengineering. Scandinavian Journal of Urology, 2015, 49, 407-414.	0.6	14
63	CD10 expression in 325 testicular germ cell tumours. Journal of Clinical Pathology, 2015, 68, 400-403.	1.0	0
64	Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e1-495.e7.	0.8	16
65	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology, 2015, 68, 819-824.	1.0	34
66	Absorption of Irrigation Fluid Occurs Frequently during High Power 532 nm Laser Vaporization of the Prostate. Journal of Urology, 2015, 193, 211-216.	0.2	21
67	Frequent expression of PD-L1 in testicular germ cell tumors Journal of Clinical Oncology, 2015, 33, 379-379.	0.8	1
68	High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer. Medical Science Monitor, 2015, 21, 2266-2274.	0.5	15
69	Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. Oncotarget, 2015, 6, 6459-6469.	0.8	11
70	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clinical Pathology, 2014, 14, 10.	1.8	61
71	HIGH POWER (80 W) POTASSIUM-TITANYL-PHOSPHATE LASER VAPORIZATION OF THE PROSTATE IN 66 HIGH RISK PATIENTS. Journal of Urology, 2005, 173, 158-160.	0.2	242